Erratum: Advances in targeted therapies for hepatocellular carcinoma in the genomic era (Nature Reviews Clinical Oncology (2015) DOI: 10.1038/nrclinonc.2015.103);Advances in targeted therapies for hepatocellular carcinoma in the genomic era

Nature Reviews Clinical Oncology

Volumn 12, Issue 7, 2015, Pages 408-424

  Llovet, Josep M ^a   Villanueva, Augusto ^a   Lachenmayer, Anja ^b   Finn, Richard S ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BETA CATENIN; BEVACIZUMAB; CABOZANTINIB; CEDIRANIB; CRIZOTINIB; DOXORUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GALUNISERTIB; JANUS KINASE; LENVATINIB; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PERETINOIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; RAMUCIRUMAB; RAPAMYCIN; RAS PROTEIN; REFAMETINIB; REGORAFENIB; SORAFENIB; STAT PROTEIN; TEMSIROLIMUS; TIVANTINIB; UNINDEXED DRUG; VORINOSTAT; WNT PROTEIN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME TRANSLOCATION; DISEASE CLASSIFICATION; DRUG EFFICACY; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; HOMEOSTASIS; HUMAN; LIVER CELL CARCINOMA; MOLECULAR DIAGNOSIS; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; UBIQUITINATION; CARCINOMA, HEPATOCELLULAR; DRUG DESIGN; GENETICS; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; MUTATION; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; HUMANS; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION;

EID: 84933277181     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.121     Document Type: Erratum

References (159)

1. Lozano R., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2095-2128 (2012
2. Ferlay J., et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, 359-386 (2015
3. AACR Cancer Progress Report Writing Committee. AACR Cancer Progress Report 2013. Clin. Cancer Res. 19, S4-S98 (2013
4. European Association for the Study of the Liver & European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012
5. Bruix J., Sherman M. & The American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 53, 1020-1022 (2011
6. Llovet J. M., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359, 1734-1739 (2002
7. Lo C. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35, 1164-1171 (2002
8. Llovet J. M. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37, 429-442 (2003
9. Kudo M., et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized phase III trial. Hepatology 60, 1697-1707 (2014
10. Llovet J. M., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008
11. Hoshida Y., et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin. Liver Dis. 30, 35-51 (2010
12. Chiang D. Y., et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 68, 6779-6788 (2008
13. Boyault S., et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42-52 (2007
14. Lee J. S., et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40, 667-676 (2004
15. Lee J. S., et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12, 410-416 (2006
16. Hoshida Y., et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385-7392 (2009
17. Yamashita T., et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68, 1451-1461 (2008
18. Lachenmayer A., et al. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin. Cancer Res. 18, 4997-5007 (2012
19. Villanueva A., et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140, 1501-1512.e2 (2011
20. Mao T. L., Chu J. S., Jeng Y. M., Lai P. L. & Hsu H. C. Expression of mutant nuclear β catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J. Pathol. 193, 95-101 (2001
21. Hoshida Y., Moeini A., Alsinet C., Kojima K. & Villanueva A. Gene signatures in the management of hepatocellular carcinoma. Semin. Oncol. 39, 473-485 (2012
22. Nault J. C., et al. A hepatocellular carcinoma 5 gene score associated with survival of patients after liver resection. Gastroenterology 145, 176-187 (2013
23. Ji J., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361, 1437-1447 (2009
24. Hoshida Y., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995-2004 (2008
25. Weinstein I. B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64 (2002
26. Horwitz E., et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov. 4, 730-743 (2014
27. Chapman P. B., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011
28. Shaw A. T., et al. Crizotinib in ROS1-rearranged non small cell lung cancer. N. Engl. J. Med. 371, 1963-1971 (2014
29. Vogelstein B. & Kinzler K. W. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004
30. Sawyers C. L. Shifting paradigms: the seeds of oncogene addiction. Nat. Med. 15, 1158-1161 (2009
31. Villanueva A. & Llovet J. M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 140, 1410-1426 (2011
32. Scholer-Dahirel A. & Schlabach M. R. Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/β-catenin signaling. Proc. Natl Acad. Sci. USA 108, 17135-17140 (2011
33. Ahn S. M., et al. Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60, 1972-1982 (2014
34. Guichard C., et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694-698 (2012
35. Kan Z., et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23, 1422-1433 (2013
36. Sawey E. T., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347-358 (2011
37. Villanueva A. & Llovet J. M. Mutational landscape of HCC-the end of the beginning. Nat. Rev. Clin. Oncol. 11, 73-74 (2014
38. Totoki Y., et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46, 1267-1273 (2014
39. Farazi P. A. & Depinho R. A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 6, 674-687 (2006
40. Villanueva A., Newell P., Chiang D., Friedman S. L. & Llovet J. M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis. 27, 55-76 (2007
41. Llovet J. M., et al. A Molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 131, 1758-1767 (2006
42. Villanueva A., et al. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 143, 1660-1669 (2012
43. Zender S., et al. A critical role for notch signaling in the formation of cholangiocellular carcinomas. Cancer Cell 23, 784-795 (2013
44. Zong Y., et al. Notch signaling controls liver development by regulating biliary differentiation. Development 136, 1727-1739 (2009
45. Zhou D., et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16, 425-438 (2009
46. Fitamant J., et al. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. Cell Rep. 10, 1692-1707 (2015
47. Wilson B. G. & Roberts C. W. M. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11, 481-492 (2011
48. Calvisi D., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130, 1117-1128 (2006
49. Newell P., et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J. Hepatol. 51, 725-733 (2009
50. Wilhelm S. M., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129-3140 (2008
51. Miura K., et al. The preclinical development of regorafenib for the treatment of colorectal cancer. Expert Opin. Drug Discov. 9, 1087-1101 (2014
52. Villanueva A., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135, 1972-1983 (2008
53. Tovar V., et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre clinical efficacy of IGF-1R blockage. J. Hepatol. 52, 550-559 (2010
54. Abou-Alfa G. K., et al. A phase II study of cixutumumab (IMC A12, NSC742460) in advanced hepatocellular carcinoma. J. Hepatol. 60, 319-324 (2014
55. Kaposi-Novak P. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 116, 1582-1595 (2006
56. Goyal L., Muzumdar M. D. & Zhu A. X. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin. Cancer Res. 19, 2310-2318 (2013
57. Zhu A. X., Duda D. G., Sahani D. V. & Jain R. K. HCC and angiogenesis: possible targets and future directions. Nat. Rev. Clin. Oncol. 8, 292-301 (2011
58. Sia D., Alsinet C., Newell P. & Villanueva A. VEGF signaling in cancer treatment. Curr. Pharm. Des. 20, 2834-2842 (2014
59. Bruix J., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421-430 (2001
60. Llovet J. M., Burroughs A. & Bruix J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003
61. Cheng A. L., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009
62. Llovet J. M., et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 18, 2290-2300 (2012
63. Bruix J., et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J. Hepatol. 57, 821-829 (2012
64. Reig M., et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J. Hepatol. 61, 318-324 (2014
65. Cammà C., et al. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology 57, 1046-1054 (2013
66. Johnson P. J., et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 31, 3517-3524 (2013
67. Cheng A. L., et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J. Clin. Oncol. 31, 4067-4075 (2013
68. Cainap C., et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 33, 172-179 (2015
69. Tai W. T., et al. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. J. Hepatol. 55, 1041-1048 (2011
70. Llovet J. M., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698-711 (2008
71. Forner A., Llovet J. M. & Bruix J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012
72. Marrero J. A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41, 707-716 (2005
73. Llovet J. M., et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 31, 3509-3516 (2013
74. Zhu A. X., Rosmorduc O., Evans J., Ross P. & Santoro A. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). J. Clin. Oncol. 33, 559-566 (2015
75. Zhu A. X., et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib. JAMA 312, 57-67 (2014
76. Zhu A. X., et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: results from the randomized phase III reach study. Ann. Oncol. 25, 1-41 (2014
77. Qin S., et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J. Clin. Oncol. 31, 3501-3508 (2013
78. Llovet J. M. & Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 20, 2072-2079 (2014
79. Llovet J. M., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29, 62-67 (1999
80. Faivre S., et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 10, 794-800 (2009
81. Zhu A. X., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 27, 3027-3035 (2009
82. Philip P. A. Phase II study of erlotinib (OSI 774) in patients with advanced hepatocellular cancer. J. Clin. Oncol. 23, 6657-6663 (2005
83. Thomas M. B., et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110, 1059-1067 (2007
84. Toh H. C., et al. Phase 2 trial of linifanib (ABT 869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer 119, 380-387 (2012
85. Finn R. S., et al. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 17, 1973-1983 (2011
86. Finn R. S., Kang Y. K., Mulcahy M. & Lim H. Y. Phase II, open-label study of brivanib as second line therapy in patients with advanced hepatocellular carcinoma. Clin. Cancer Res. 18, 2090-2098 (2012
87. Villanueva A. & Llovet J. M. Second-line therapies in hepatocellular carcinoma: emergence of resistance to sorafenib. Clin. Cancer Res. 18, 1824-1826 (2012
88. Zhu A. X., et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor 2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin. Cancer Res. 19, 6614-6623 (2013
89. Llovet J. M., Schwartz M. & Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin. Liver Dis. 25, 181-200 (2005
90. Takayama T., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356, 802-807 (2000
91. Muto Y., et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 334, 1561-1567 (1996
92. Bruix J., Takayama T., Mazzaferro V., Chau G. Y. & Yang J. STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma [abstract]. J. Clin. Oncol. 32, a4006 (2014
93. Simon R., Thall P. F. & Ellenberg S. S. New designs for the selection of treatments to be tested in randomized clinical trials. Stat. Med. 13, 417-429 (1994
94. Abou-Alfa G. K., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24, 4293-4300 (2006
95. Reig M., et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 58, 2023-2031 (2013
96. Lencioni R. & Llovet J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52-60 (2010
97. Karapetis C. S., et al. K ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008
98. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01755767 (2015
99. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01915602 (2015
100. Siegel P. M. & Massagué J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat. Rev. Cancer 3, 807-821 (2003
101. Principe D. R., et al. TGF β: duality of function between tumor prevention and carcinogenesis. J. Natl Cancer Inst. 106, djt369-djt369 (2014
102. Giannelli G., Villa E. & Lahn M. Transforming growth factor β as a therapeutic target in hepatocellular carcinoma. Cancer Res. 74, 1890-1894 (2014
103. Coulouarn C., Factor V. M. & Thorgeirsson S. S. Transforming growth factor β gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47, 2059-2067 (2008
104. Dituri F., et al. Differential Inhibition of the TGF β signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF β receptor type II. PLoS ONE 8, e67109 (2013
105. Faivre S. J., Santoro A. & Kelley R. K. A phase 2 study of a novel transforming growth factor-beta (TGF-β 1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma [abstract]. J. Clin. Oncol. 32, LBA173 (2014
106. Roberts L. R. Fibroblast growth factor signaling in liver carcinogenesis. Hepatology 59, 1166-1173 (2014
107. Casanovas O., Hicklin D. J., Bergers G. & Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005
108. Nicholes K., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 160, 2295-2307 (2002
109. Desnoyers L. R., et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 27, 85-97 (2008
110. Finn R. S., et al. Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398 in vitro. Cancer Res. 72, 3858-3858 (2012
111. Guagnano V., et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2, 1118-1133 (2012
112. Hagel M., et al. First isoform selective inhibitor of FGFR4 for the treatment of genomically defined patients with hepatocellular carcinoma [abstract]. Cancer Res. 74, LB 324 (2014
113. Ryan D. P., Hong T. S. & Bardeesy N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 1039-1049 (2014
114. Hauschild A., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365 (2012
115. Flaherty K. T., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703 (2012
116. O'Neil B. H., et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 29, 2350-2356 (2011
117. Schmieder R., et al. Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia 15, 1161-1171 (2013
118. Lim H. Y., et al. A Phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin. Cancer Res. 20, 5976-5985 (2014
119. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01915602?term=refametiniamp;b&rank=4 (2015
120. Pardoll D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012
121. Hodi F. S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010
122. Hamid O., et al. Safety and tumor responses with lambrolizumab (anti PD 1) in melanoma. N. Engl. J. Med. 369, 134-144 (2013
123. Okazaki T., Chikuma S., Iwai Y., Fagarasan S. & Honjo T. A rheostat for immune responses: the unique properties of PD 1 and their advantages for clinical application. Nat. Immunol. 14, 1212-1218 (2013
124. Butterfield L. H., et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin. Cancer Res. 12, 2817-2825 (2006
125. Palmer D. H., et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology 49, 124-132 (2009
126. A clinical trial of CTLA 4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. Hepatology 59, 81-88 (2013
127. Robert C., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320-330 (2015
128. Garon E. B., et al. MK 3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): preliminary safety and clinical activity [abstract]. Clin. Cancer Res. 20, A20 (2014
129. Santoro A., et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 14, 55-63 (2013
130. Xiang Q., et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. Clin. Cancer Res. 20, 2959-2970 (2014
131. Calles A., et al. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non small cell lung cancer cell lines. Mol. Oncol. 9, 260-269 (2015
132. Mudbhary R., et al. UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer Cell 25, 196-209 (2014
133. Shen Y. C., et al. Clinical trials in hepatocellular carcinoma: an update. Liver Cancer 2, 345-364 (2013
134. Yeo W., et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo phase II consortium and the cancer therapeutics research group. J. Clin. Oncol. 30, 3361-3367 (2012
135. Khan O., et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA 107, 6532-6537 (2010
136. Bitzer M., Horger M., Ganten T., Lauer U. M. & Woerns M. A. Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): phase II shelter study [abstract]. J. Clin. Oncol. 30, 4115 (2013
137. Lachenmayer A., et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J. Hepatol. 56, 1343-1350 (2012
138. Toffanin S., et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR 517a. Gastroenterology 140, 1618-1628e16 (2011
139. Ling H., Fabbri M. & Calin G. A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 12, 847-865 (2013
140. Maurel M., et al. A functional screening identifies five microRNAs controlling glypican 3: role of mir 1271 down-regulation in hepatocellular carcinoma. Hepatology 57, 195-204 (2013
141. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01507168 (2015
142. Kota J., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017 (2009
143. Baccarani M., et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122, 872-884 (2013
144. Rudalska R., et al. RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat. Med. 20, 1138-1146 (2014
145. Molina M. A., et al. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61, 4744-4749 (2001
146. Shaw A. T., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385-2394 (2013
147. O'Brien S. G., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 348, 994-1004 (2003
148. Paez J. G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004
149. Slamon D. J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001
150. Kwak E. L., et al. Anaplastic lymphoma kinase inhibition in non small cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010
151. Mitchell M. S. & Press M. F. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin. Oncol. 26, 108-116 (1999
152. Gerlinger M., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012
153. Friemel J., et al. Intratumor heterogeneity in hepatocellular carcinoma. Clin. Cancer Res. 21, 1951-1961 (2014
154. Chen Y. J., et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 119, 431-440 (2000
155. Tao Y., et al. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc. Natl Acad. Sci. USA 108, 12042-12047 (2011
156. Crowley E., Di Nicolantonio F., Loupakis F. & Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10, 472-484 (2013
157. Fujimoto A., et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760-764 (2012
158. Li M., et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat. Genet. 43, 828-829 (2011
159. Altman D. G. & Bland J. M. How to obtain the P value from a confidence interval. BMJ 343, d2304 (2011